Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA, Bilthoven, The Netherlands.
Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Sci Rep. 2022 Apr 8;12(1):5935. doi: 10.1038/s41598-022-10020-6.
mRNA- and vector-based vaccines are used at a large scale to prevent COVID-19. We compared Spike S1-specific (S1) IgG antibodies after vaccination with mRNA-based (Comirnaty, Spikevax) or vector-based (Janssen, Vaxzevria) vaccines, using samples from a Dutch nationwide cohort. In adults 18-64 years old (n = 2412), the median vaccination interval between the two doses was 77 days for Vaxzevria (interquartile range, IQR: 69-77), 35 days (28-35) for Comirnaty and 33 days (28-35) for Spikevax. mRNA vaccines induced faster inclines and higher S1 antibodies compared to vector-based vaccines. For all vaccines, one dose resulted in boosting of S1 antibodies in adults with a history of SARS-CoV-2 infection. For Comirnaty, two to four months following the second dose (n = 196), S1 antibodies in adults aged 18-64 years old (436 BAU/mL, IQR: 328-891) were less variable and median concentrations higher compared to those in persons ≥ 80 years old (366, 177-743), but differences were not statistically significant (p > 0.100). Nearly all participants seroconverted following COVID-19 vaccination, including the aging population. These data confirm results from controlled vaccine trials in a general population, including vulnerable groups.
mRNA 疫苗和载体疫苗被大规模用于预防 COVID-19。我们比较了使用 mRNA 疫苗（Comirnaty、Spikevax）或载体疫苗（Janssen、Vaxzevria）接种后的 Spike S1 特异性（S1）IgG 抗体，使用了来自荷兰全国队列的样本。在 18-64 岁的成年人中（n=2412），Vaxzevria 的两剂疫苗接种间隔中位数为 77 天（四分位距，IQR：69-77），Comirnaty 为 35 天（28-35），Spikevax 为 33 天（28-35）。与载体疫苗相比，mRNA 疫苗诱导的 S1 抗体上升更快，水平更高。对于所有疫苗，一剂疫苗可使有 SARS-CoV-2 感染史的成年人的 S1 抗体得到增强。对于 Comirnaty，第二剂疫苗接种后 2-4 个月（n=196），18-64 岁成年人的 S1 抗体（436 BAU/mL，IQR：328-891）较 80 岁及以上人群（366，177-743）的抗体变异较小，中位数浓度较高，但差异无统计学意义（p＞0.100）。几乎所有参与者在 COVID-19 疫苗接种后均发生血清转化，包括老年人群。这些数据证实了在一般人群中包括弱势群体在内的对照疫苗试验的结果。
